BACKGROUND: Newly developed troponin assays have superior diagnostic and prognostic performance in acute coronary syndrome (ACS), when compared to conventional troponin assays; however, highly sensitive troponin has not been evaluated in patients with acute ischemic stroke. METHODS: Highly sensitive troponin T (hsTnT) was measured daily during the first 4 days in 193 consecutive patients with acute ischemic stroke without overt ACS or atrial fibrillation. The patients were previously tested normal with a fourth-generation TnT assay. The patients were followed for 47 months, with all-cause and cardiovascular mortality end-points. RESULTS: A total of 33.7% of the patients had hsTnT levels >14 ng/l following admission. Patients with increased hsTnT were older, had decreased hemoglobin levels and increased creatinine, NT-proBNP and CRP levels. hsTnT concentrations at admission were significantly higher in decedents than in survivors. After adjustment for stroke severity, C-reactive protein, age, NT-proBNP and prior heart and/or renal failure, hsTnT levels were not a significant predictor of long-term all-cause or cardiovascular mortality. CONCLUSION: Elevated levels of hsTnT are frequently present in patients with acute ischemic stroke previously tested normal with a fourth-generation TnT assay. hsTnT did not provide additional prognostic information in these subjects.
BACKGROUND: Newly developed troponin assays have superior diagnostic and prognostic performance in acute coronary syndrome (ACS), when compared to conventional troponin assays; however, highly sensitive troponin has not been evaluated in patients with acute ischemic stroke. METHODS: Highly sensitive troponin T (hsTnT) was measured daily during the first 4 days in 193 consecutive patients with acute ischemic stroke without overt ACS or atrial fibrillation. The patients were previously tested normal with a fourth-generation TnT assay. The patients were followed for 47 months, with all-cause and cardiovascular mortality end-points. RESULTS: A total of 33.7% of the patients had hsTnT levels >14 ng/l following admission. Patients with increased hsTnT were older, had decreased hemoglobin levels and increased creatinine, NT-proBNP and CRP levels. hsTnT concentrations at admission were significantly higher in decedents than in survivors. After adjustment for stroke severity, C-reactive protein, age, NT-proBNP and prior heart and/or renal failure, hsTnT levels were not a significant predictor of long-term all-cause or cardiovascular mortality. CONCLUSION: Elevated levels of hsTnT are frequently present in patients with acute ischemic stroke previously tested normal with a fourth-generation TnT assay. hsTnT did not provide additional prognostic information in these subjects.
Authors: Michiel Rienstra; Xiaoyan Yin; Martin G Larson; João D Fontes; Jared W Magnani; David D McManus; Elizabeth L McCabe; Erin E Coglianese; Michael Amponsah; Jennifer E Ho; James L Januzzi; Kai C Wollert; Michael G Fradley; Ramachandran S Vasan; Patrick T Ellinor; Thomas J Wang; Emelia J Benjamin Journal: Am Heart J Date: 2013-10-17 Impact factor: 4.749
Authors: Alexander E Merkler; Gino Gialdini; Santosh B Murthy; Setareh Salehi Omran; Antonio Moya; Michael P Lerario; Ji Chong; Peter M Okin; Jonathan W Weinsaft; Monika M Safford; Matthew E Fink; Babak B Navi; Costantino Iadecola; Hooman Kamel Journal: J Am Heart Assoc Date: 2017-09-22 Impact factor: 5.501
Authors: Helena Stengl; Ramanan Ganeshan; Simon Hellwig; Edyta Blaszczyk; Jochen B Fiebach; Christian H Nolte; Axel Bauer; Jeanette Schulz-Menger; Matthias Endres; Jan F Scheitz Journal: JMIR Res Protoc Date: 2021-02-05
Authors: Michael D Hill; Renee H Martin; Yuko Y Palesch; Claudia S Moy; Diego Tamariz; Karla J Ryckborst; Elizabeth B Jones; David Weisman; Creed Pettigrew; Myron D Ginsberg Journal: PLoS One Date: 2015-09-01 Impact factor: 3.240
Authors: Nicole Nigro; Karin Wildi; Christian Mueller; Philipp Schuetz; Beat Mueller; Felix Fluri; Mirjam Christ-Crain; Mira Katan Journal: PLoS One Date: 2014-07-29 Impact factor: 3.240